STROKE-ANTIPLATELET THERAPY

SUMMARY

1. For patients with non-cardioembolic ischemic stroke or TIA, the risk of recurrent stroke and other events is reduced with 2 antiplatelet agents: Aspirin & Clopidogrel.

2. Commence both agents within 24 hours, continue for 3 weeks, then mono-therapy for life.

3. Antiplatelet medications have been shown to be beneficial in the secondary stroke prevention of presumed arterial origin.

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].